Recall for Tablets Distributed in 2 States

Preferred Pharmaceuticals Inc. is recalling 266 bottles of ibuprofen tablets distributed in California and Nevada, according to the September 4, 2024, US Food and Drug Administration (FDA) Enforcement Report. The affected tablets failed to meet impurity/degradation specifications during 18-month stability testing.

The recall affects 400-mg ibuprofen tablets in 30-count bottles (NDC 68788-9110-03) from lots B0223H (Exp. 5/31/26) and C3023H (Exp. 9/30/26). The manufacturer was Dr Reddy’s Laboratories, Shreveport, Louisiana.

Preferred Pharmaceuticals Inc. voluntarily initiated the recall on August 8, 2024. The FDA designated it Class II on August 26, 2024. Drugs affected by Class II recalls may cause temporary or medically reversible adverse health consequences if used. While remote, a possibility of serious harm also exists.

Ibuprofen tablets 400 mg are a nonsteroidal anti-inflammatory drug (NSAID) available with a prescription. They are indicated for the relief of mild to moderate pain, relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis, and for the treatment of primary dysmenorrhea.